Pitavastatin-attenuated cardiac dysfunction in mice with dilated cardiomyopathy via regulation of myocardial calcium handling proteins
C57BL/6 mice with dilated cardiomyopathy (DCM) were randomly divided to receive placebo or pitavastatin at a dose of 1 or 3 mg kg-1d-1. After 8 weeks treatment, mice with dilated cardiomyopathy developed serious cardiac dysfunction characterized by significantly enhanced left ventricular end-diastol...
Main Authors: | Hu Wei, Jiang Wen-Bing |
---|---|
Format: | Article |
Language: | English |
Published: |
Sciendo
2014-03-01
|
Series: | Acta Pharmaceutica |
Subjects: | |
Online Access: | http://www.degruyter.com/view/j/acph.2014.64.issue-1/acph-2014-0004/acph-2014-0004.xml?format=INT |
Similar Items
-
Mini-Review on the efficacy and safety of pitavastatin: “The novel seventh statin gaining momentum”
by: Azza Ramadan, et al.
Published: (2022-01-01) -
Structures of PKA–phospholamban complexes reveal a mechanism of familial dilated cardiomyopathy
by: Juan Qin, et al.
Published: (2022-03-01) -
Activation of sarcolipin expression and altered calcium cycling in LMNA cardiomyopathy
by: Blanca Morales Rodriguez, et al.
Published: (2020-07-01) -
Pitavastatin ameliorates myocardial damage by preventing inflammation and collagen deposition via reduced free radical generation in isoproterenol-induced cardiomyopathy
by: Ramsha Iqbal, et al.
Published: (2019-07-01) -
Benefit–risk assessment of pitavastatin for the treatment of hypercholesterolemia in older patients
by: Chamberlin KW, et al.
Published: (2015-04-01)